The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Neurotoxicity of calcineurin inhibitors: impact and clinical management
Abstract
Between 10%-28% of patients who receive the immunosuppressant cyclosporine (CsA) experience some form of neurotoxic adverse event. Both sensorial motoric functions may be adversely affected, and thus patients present with a wide range of neurological and psychiatrical disorders. Mild symptoms are common and include tremor, neuralgia, and peripheral neuropathy. Severe symptoms affect up to 5 % of patients and include psychoses, hallucinations, blindness, seizures, cerebellar ataxia, motoric weakness, or leukoencephalopathy. Tacrolimus is associated with similar neurotoxic adverse events. Neurotoxicity may result in serious complications for some patients, particularly recipients of orthotopic liver transplants. Factors that may promote the development of serious complications include advanced liver failure, hypertension, hypocholesterolemia, elevated CsA or tacrolimus blood levels, hypomagnesemia, and methylprednisolone. Occipital white matter appears to be uniquely susceptible to the neurotoxic effects of CsA; injury to both the major and minor vasculature may cause hypoperfusion or ischemia and local secondary toxicity in the white matter. Calcineurin inhibition by CsA and tacrolimus alters sympathetic outflow, which may play a role in the mediation of neurotoxic and hypertensive adverse events. The symptoms of CsA- and tacrolimus-associated neurotoxicity may be reversed in most patients by substantially reducing the dosage of immunosuppressant or discontinuing these drugs. However, some patients have experienced permanent or even fatal neurological damage even after dose reduction or discontinuation. CsA-sparing and tacroli-mus-sparing drug regimens that use the immunosuppressant mycophenolate mofetil, which has no neurotoxic effects, may reduce the incidence and severity of neurotoxic adverse events while maintaining an adequate level of immunoisuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, R., & Eisenberg, S. (1990) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02934-6 · Cited by 2,720
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Protein synthesis and memory: A review.
Davis, H. P., & Squire, L. R. (1984) · Psychological Bulletin · doi:10.1037//0033-2909.96.3.518 · Cited by 1,503
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., et al. (1997) · Transplantation · doi:10.1097/00007890-199708150-00012 · Cited by 724
Central Nervous System Toxicity after Liver Transplantation
de Groen, P. C., Aksamit, A. J., Rakela, J., Forbes, G. S., & Krom, R. A. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710013171404 · Cited by 498
Cyclosporine-Induced Sympathetic Activation and Hypertension after Heart Transplantation
Scherrer, U., Vissing, S. F., Morgan, B. J., Rollins, J. A., Tindall, R. S. A., Ring, S., Hanson, P., Mohanty, P. K., & Victor, R. G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009133231101 · Cited by 408
ASSOCIATION BETWEEN CYCLOSPORIN NEUROTOXICITY AND HYPOMAGNESAEMIA
Thompson, C., Sullivan, K., June, C., & Thomas, E. D. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91556-3 · Cited by 340
Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin
Ferreira, P. A., Nakayama, T. A., Pak, W. L., & Travis, G. H. (1996) · Nature · doi:10.1038/383637a0 · Cited by 216
FK506 and the role of immunophilins in nerve regeneration
Gold, B. G. (1997) · Molecular Neurobiology · doi:10.1007/bf02740664 · Cited by 191
Respiratory modulation of muscle sympathetic nerve activity in intact and lung denervated humans.
Seals, D. R., Suwarno, N. O., Joyner, M. J., Iber, C., Copeland, J. G., & Dempsey, J. A. (1993) · Circulation Research · doi:10.1161/01.res.72.2.440 · Cited by 180
NEUROTOXICITY AFTER ORTHOTOPIC LIVER TRANSPLANTATION
Mueller, A. R., Platz, K.-P., Bechstein, W.-O., Schattenfroh, N., Stoltenburg-Didinger, G., Blumhardt, G., Christe, W., & Neuhaus, P. (1994) · Transplantation · doi:10.1097/00007890-199405820-00006 · Cited by 161
Self-citationFK506‐induced neurotoxicity in liver transplantation
Wijdicks, E. F. M., Wiesner, R. H., Dahlke, L. J., & Krom, R. A. F. (1994) · Annals of Neurology · doi:10.1002/ana.410350422 · Cited by 159
Cerebral blindness and encephalopathy with cyclosporin A toxicity
RUBIN, A. M., & Kang, H. (1987) · Neurology · doi:10.1212/wnl.37.6.1072 · Cited by 149
The design and development of an immunosuppressive drug, mycophenolate mofetil
ALLISON, A. C., & Eugui, E. M. (1993) · Springer Seminars in Immunopathology · doi:10.1007/bf00192309 · Cited by 146
Dawson, T. M., Steiner, J. P., Lyons, W. E., Fotuhi, M., Blue, M. E., & Snyder, S. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90389-1 · Cited by 137
Clinically Significant Drug Interactions with New Immunosuppressive Agents
Mignat, C. (1997) · Drug Safety · doi:10.2165/00002018-199716040-00004 · Cited by 133
Smith, T., Ferreira, L. R., HEBERT, C. A., Norris, K., & Sauk, J. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18323 · Cited by 125
Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures
McDonald, J. W., Goldberg, M. P., Gwag, B. J., Chi, S., & Choi, D. W. (1996) · Annals of Neurology · doi:10.1002/ana.410400511 · Cited by 125
Sympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*
Sander, M., Lyson, T., Thomas, G. D., & Victor, R. G. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00288-9 · Cited by 118
Sensorimotor neuropathy resembling CIDP in patients receiving FK506
Wilson, J. R., CONWIT, R. A., Eidelman, B. H., Starzl, T. E., & Abu-Elmagd, K. M. (1994) · Muscle & Nerve · doi:10.1002/mus.880170510 · Cited by 116
Interactions Between Tacrolimus and Antimicrobial Agents
Paterson, D. L., & Singh, N. (1997) · Clinical Infectious Diseases · doi:10.1086/516138 · Cited by 116
Eckhoff, D. E., McGuire, B. M., Frenette, L., et al. (1998) · Transplantation · doi:10.1097/00007890-199801270-00006 · Cited by 114
NEUROLOGIC COMPLICATIONS OF LIVER TRANSPLANTATION
VOGT, D. P., Lederman, R. J., CAREY, W. D., & Broughan, T. A. (1988) · Transplantation · doi:10.1097/00007890-198806000-00011 · Cited by 113
Cyclosporine: mechanisms of action and toxicity
Brouhard, B. H., & Graham, R. M. (1994) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.61.4.308 · Cited by 111
Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin
Cardenas, M. E., Zhu, D., & Heitman, J. (1995) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199511000-00002 · Cited by 109
Neurologic Complications of Immunosuppressive Agents
Walker, R., & Brochstein, J. A. (1988) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30869-7 · Cited by 100
The Site of the Earliest Lesions of Alzheimer's Disease
Mann, D. M. A., & Esiri, M. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198803243181218 · Cited by 94
Lyson, T., Ermel, L. D., Belshaw, P. J., Alberg, D. G., Schreiber, S. L., & Victor, R. G. (1993) · Circulation Research · doi:10.1161/01.res.73.3.596 · Cited by 88
Neurological complications of liver transplantation
Guarino, M., Stracciari, A., Pazzaglia, P., et al. (1996) · Journal of Neurology · doi:10.1007/bf02444004 · Cited by 79
Grimm, M. F., Yeganehfar, W., Laufer, G., Madl, C., Kramer, L., Eisenhuber, E., Simon, P., Kupilik, N., Schreiner, W., Pacher, R., et al. (1996) · Circulation · doi:10.1161/01.cir.94.6.1339 · Cited by 77
Lu, Y., Tomizawa, K., Moriwaki, A., Hayashi, Y., Tokuda, M., Itano, T., Hatase, O., & Matsui, H. (1996) · Brain Research · doi:10.1016/0006-8993(96)00568-9 · Cited by 59
Mycophenolate mofetil added to immunosuppression after liver transplantation - first results
Klupp, J., Bechstein, W. O., Platz, K. P., Keck, H., Lemmens, H. P., Knoop, M., Langrehr, J. M., Neuhaus, R., Pratschke, J., & Neuhaus, P. (1997) · Transplant International · doi:10.1007/s001470050046 · Cited by 52
Self-citationSerkova, N. J., Brand, A., Christians, U., & Leibfritz, D. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(96)00081-x · Cited by 50
Cyclosporin A, an inhibitor of calcineurin, impairs memory formation in day-old chicks
Bennett, P. C., Weiqin, Z., Lawen, A., & Ng, K. T. (1996) · Brain Research · doi:10.1016/0006-8993(96)00441-6 · Cited by 48
Martina, M., Mozrzymas, J. W., Boddeke, H. W. G. M., & Cherubini, E. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12957-8 · Cited by 36
Epileptiform electroencephalographic abnormalities in liver transplant recipients
Wszołek, Z. K., Aksamit, A. J., Ellingson, R. J., et al. (1991) · Annals of Neurology · doi:10.1002/ana.410300108 · Cited by 35
Important interactions of drugs with immunosuppressive agents used in transplant recipients
Lake, K. D., & Canafax, D. M. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.suppl_b.11 · Cited by 35
Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506
Tezcan, H., Zimmer, W., Fenstermaker, R. A., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701047 · Cited by 29
Peptidyl‐prolyl‐cis/trans‐isomerase activity may be necessary for memory formation
Bennett, P. C., Singaretnam, L. G., Zhao, W., Lawen, A., & Ng, K. T. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00795-9 · Cited by 26
Cyclosporin Metabolism in Human Liver Microsomes and Its Inhibition by Other Drugs
Henricsson, S., Lindholm, A., & Aravoglou, M. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00701.x · Cited by 22
McMichael, J. P., Lieberman, R., Doyle, H. R., McCauley, J., Fung, J. J., & Starzl, T. E. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb04711.x · Cited by 18
Cited by
NFAT proteins: key regulators of T-cell development and function
Macian, F. (2005) · Nature Reviews Immunology · doi:10.1038/nri1632 · Cited by 1,569
How I treat hemophagocytic lymphohistiocytosis
Jordan, M. B., Allen, C. E., Weitzman, S., Filipovich, A. H., & McClain, K. L. (2011) · Blood · doi:10.1182/blood-2011-03-278127 · Cited by 1,148
Clinical pancreatic islet transplantation
Shapiro, A. M. J., Pokrywczynska, M., & Ricordi, C. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.178 · Cited by 747
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia
Miyakawa, T., Leiter, L. M., Gerber, D. J., Gainetdinov, R. R., Sotnikova, T. D., Zeng, H., Caron, M. G., & Tonegawa, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432926100 · Cited by 489
Neurological complications in renal failure: a review
Brouns, R., & De Deyn, P. P. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.07.012 · Cited by 392
Metadata
- Authors
- Bechstein, W. O.
- Venue
- Transplant International
- Publisher
- Frontiers Media SA
- Published
- 2000-09-14
- Volume
- 13
- Issue
- 5
- Pages
- 313-326
- ISSN
- 0934-0874 (ISSN-L)
- 1432-2277
- OpenAlex
- W4241551895
- Cited by
- 578
- References
- 42
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.